Akeso, Inc. Announces Presentation of Real-World Study At the 2026 American Society of Clinical Oncology Gastrointestinal Cancers Symposium
I'm PortAI, I can summarize articles.
Akeso, Inc. announced a real-world study presentation at the 2026 ASCO GI Symposium, comparing cadonilimab plus chemotherapy to a PD-1 inhibitor plus chemotherapy for advanced gastric cancer treatment. Results showed significant improvements in overall survival (OS) and progression-free survival (PFS) for the cadonilimab regimen. The study addresses the unmet clinical need for PD-L1-low or negative patients, as current PD-1 therapies are limited to PD-L1-positive cases. Akeso is advancing Phase III studies for cadonilimab, with FDA approval for the COMPASSION-37 study expected by late 2025.
Source: marketscreener The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments